Your session is about to expire
← Back to Search
Non-small cell Lung Cancer for Non-Small Cell Lung Cancer
N/A
Waitlist Available
Research Sponsored by Biological Dynamics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up standard of care (approximately every 6 weeks to 3 months) for 6- 9 months
Awards & highlights
Summary
The TR(ACE) Assay is a quantitative in vitro diagnostic test run on the TR(ACE) Instrument intended for the measurement of high molecular weight human DNA from plasma as an aid to monitoring disease progression or response to therapy or recurrent or residual disease.
Eligible Conditions
- Non-Small Cell Lung Cancer
- Breast Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ standard of care (approximately every 6 weeks to 3 months) for 6- 9 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~standard of care (approximately every 6 weeks to 3 months) for 6- 9 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Clinical Assessment change
Secondary study objectives
RECIST 1.1 criteria
Trial Design
2Treatment groups
Experimental Treatment
Group I: Non-small cell Lung CancerExperimental Treatment1 Intervention
Previously diagnosed stage III or higher non-small cell lung cancer subjects will provide serial plasma specimens and clinical assessment information over time
Group II: Breast CancerExperimental Treatment1 Intervention
Previously diagnosed stage IV breast cancer subjects will provide serial plasma specimens and clinical assessment information over time.
Find a Location
Who is running the clinical trial?
Biological DynamicsLead Sponsor
1 Previous Clinical Trials
1,000 Total Patients Enrolled
Robert KovelmanStudy DirectorBiological Dynamics
Share this study with friends
Copy Link
Messenger